Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Should You Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares gapped up before the market opened on Wednesday . The stock had previously closed at $35.15, but opened at $36.05. Nanobiotix shares last traded at $35.7960, with a volume of 7,275 shares.

Analysts Set New Price Targets

A number of equities analysts have recently commented on NBTX shares. Guggenheim started coverage on Nanobiotix in a research note on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Finally, Leerink Partners upped their price target on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 4th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $46.67.

Nanobiotix Stock Down 0.4%

The firm has a 50 day moving average price of $39.00 and a two-hundred day moving average price of $37.38.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.